

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2008 (08.05.2008)

PCT

(10) International Publication Number
WO 2008/053131 A1

(51) International Patent Classification:

C07D 239/42 (2006.01) *A61P 19/02* (2006.01)
A61K 31/506 (2006.01) *A61P 25/28* (2006.01)
A61P 7/12 (2006.01) *A61P 29/00* (2006.01)
A61P 9/00 (2006.01)

Park, Abingdon, Oxfordshire OX14 4RY (GB). **DAVID-SON, Alan, Hornsby** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DRUMMOND, Alan, Hastings** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(21) International Application Number:

PCT/GB2006/004034

(74) Agent: **WALLS, Alan, James**; P.O. Box 223, Tadworth, Surrey KT20 5YF (GB).

(22) International Filing Date: 30 October 2006 (30.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **CHROMA THERAPEUTICS LTD.** [GB/GB]; 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOFFAT, David, Festus, Charles** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DAY, Francesca, Ann** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **PATEL, Sanjay, Ratilal** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **BELFIELD, Andrew, James** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DONALD, Alistair, David, Graham** [GB/GB]; Chroma Therapeutics Ltd., 92 Milton



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE




(B1)



(B2)




(B3)



(B4)



(B5)



(B6)

(57) Abstract: Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent -N= or -C=; B is a divalent radical selected from (B1), (B2), (B3), (B4), (B5) and (B6), wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical; and R is (a) a radical of formula $R_1R_2CHNH-Y-L^1-X^1-(CH_2)_Z-$ or (b) a radical of formula $R-L^1-Y^1-(CH_2)_Z-$.